Improved survival with ipilimumab in patients with metastatic …
https://pubmed.ncbi.nlm.nih.gov/20525992/
Background: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with …
DA: 65 PA: 58 MOZ Rank: 87